TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07875270: Usability and Clinical Validation of the Flu A/B/COVID-19 + RSV Multiplex Rapid Test

Sponsor: CorDx, Inc. · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 1500 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$9,408,000

Rescue Site Savings

+$6,203,400

Unlock Full NCT07875270 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07875270 Rescue Dossier →